Announcements Trials
Browse Landscape

Status

Recruiting 6Active not recruiting 6Terminated 2Withdrawn 1Not yet recruiting 1Completed 1Available 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 5Pancreatic Neoplasms 5Multiple Myeloma 5Melanoma 5Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Glioblastoma 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Primary Myelofibrosis 2Non-Muscle Invasive Bladder Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2

Interventions

mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × INDUSTRY × Neurofibroma, Plexiform × Clear all
NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Available
CNS

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡